Products

Online Inquiry

Name

Email *

Phone *

Company/Institution

Country or Region

Quantity

Services & Products Interested *

Project Description

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Dasatinib (BMS-354825)

inquiry

Cat No.

CEI-0259

Description

As a potent and multi-targeted inhibitor, dasatinib (BMS-354825) can inhibit Abl, Src and c-Kit, with IC50 of <1 nM, 0.5 nM and 79 nM, respectively.

Alias

Sprycel

CAS No.

302962-49-8

Molecular Weight

488.01

Purity

>99%

Storage

2 years at -20 centigrade

Synonyms

Sprycel

Targets

Abl, Src, c-Kit

Molecular Formula

C22H26ClN7O2S

Chemical Name

N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

Solubility

DSMO 98 mg/mL Water

In vitro

As a potent and multi-targeted inhibitor, dasatinib (BMS-354825) can inhibit Abl, Src and c-Kit, with IC50 of (1) In HNSCC and NSCLC cells. In HNSCC and NSCLC cells, dasatinib induced cell cycle arrest by blocking the G1-S transition, and dasatinib can also result in apoptosis in some lines. By influencing Src and downstream mediators of adhesion, including focal adhesion kinase (FAK), p130, and paxillin, dasatinib showed effects on migration and invasion. By inducing p27 and the dephosphorylation of Rb, dasatinib showed effects on cell cycle and apoptosis. Dasatinib also induced morphologic changes that were consistent with an upstream role for Src in regulating focal adhesion complexes. (2) In human prostate cancer cells. Dasatinib blocks the kinase activities of the SFKs, Lyn, and Src, in human prostate cancer cells at low nanomolar concentrations. Focal adhesion kinase and Crk-associated substrate (p130(CAS)) signaling downstream of SFKs are also inhibited at similar concentrations of dasatinib. Dasatinib suppresses cell adhesion, migration, and invasion of prostate cancer cells at low nanomolar concentrations. (3) In imatinib-resistant cells. As a novel small molecule, Dasatinib showed potent inhibition to imatinib-resistant cell lines, malignant marrow cells isolated from patients with imatinib-resistant CML (chronic myeloid leukemia).